You are currently logged into
Cancer Health Directory - My Account or Log Out
Cancer Health Cancer Health
  • Home
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Cancer Health TV
    • By Author
    • RSS Links
  • Cancer Basics
    • Cancer 101
    • Newly Diagnosed
    • Living with Cancer
    • Cancer Treatment
    • Cancer Medications
    • Breast Cancer
    • Colon Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • More Types of Cancer
    • Resources
  • Hot Topics
    • Coronavirus (COVID-19)
    • Health Equity
    • Cancer Treatment
    • Car-T Therapy
    • Caregivers
    • Chemotherapy
    • Immunotherapy
    • Marijuana
    • Mental Health
    • Quality of Life
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Cancer Health Focus
    • Bulk Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Cancer Health Stories
    • Cancer Health Forums
    • Ask Cancer Health
    • Polls
    • Surveys
    • Quizzes
    • Calendar
    • Volunteer Jobs
    • Bookstore
    • Amazon Store
  • About Us
    • About Us
    • Masthead
    • Advertise
    • Awards
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Rubraca

Tweet
  • Share

FDA Approves Liquid Biopsy Test For Multiple Cancers and Biomarkers

The blood test identifies biomarkers that could make patients eligible for targeted therapies.

Rubraca

Male reproductive system

FDA Approves Rubraca for BRCA-Mutated Metastatic Prostate Cancer

More than 40% of people treated with the PARP inhibitor saw tumor shrinkage.

PARP Inhibitor Delays Pancreatic Cancer Recurrence

Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.

PARP Inhibitor Shows Promise for Advanced Prostate Cancer

Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.

FDA Approves Rubraca for Ovarian Cancer Maintenance Treatment

Study showed patients receiving rucaparib had significant improvement in progression-free survival.

3D rendering of the breast

New PARP Inhibitor Improves Survival in Women With Advanced Breast Cancer

Talazoparib may offer an additional option for women with BRCA gene mutations.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.